Loading...

RNAZ TRANSCODE THERAPEUTICS INC Management Changes 8-K Filing

TRNS

RNZ

TRANSCODE THERAPEUTICS INC

(RNAZ)

2026 8-K

Clinical Trial Update

2026 Annual Meeting

Compliance Notification

Nasdaq Deficiency Notice

Equity Purchase Agreement

New Licensing Agreement

Research Publication News

FDA Application Update

Research Announcement

Company Acquisition

Director Appointment

New Collaboration

Stock Preference Update

Contingent Value Rights

Clinical Trial Update

Acquisition Announcement

Company Acquisition

License Agreement Update

Annual Meeting Results

Annual Meetings

Forced Delisting

Reverse Stock Split

Stockholder Meeting

Stockholder Meeting

Special Meeting Adjourned

Clinical Trial Update

Private Placement

Stock Split Announcement

Stockholder Approvals

Nasdaq Compliance

Nasdaq Compliance Issues

Nasdaq Compliance Issues

Nasdaq Deficiencies

Public Offering

Amendment to Voting Results

Annual Meeting of Stockholders

Compliance with Nasdaq List...

Annual Meeting Announcement

Financial Results Announcement

Compliance Regained

Securities Purchase Agreement

Financial Estimate

Special Meeting of Stockhol...

Bylaw Amendment

Registered Direct Offering

Earnings Reports

Delisting Notice

Clinical Results Announcement

Public Offering

Clinical Trial Announcement

Securities Purchase Agreement

Reverse Stock Split

Retention Program

Annual Meeting of Stockholders

Stock Purchase Agreement

Annual Meeting Announcement

Financial Results Announcement

Securities Purchase Agreement

Financial Update

External Links:

On June 3, 2026, Transcode Therapeutics, Inc. announced further results from its Phase 1a clinical trial of TTX-MC138, indicating progress in their cancer treatment research. This event is significant for the company as they advance in drug development.

AI Assistant

TRANSCODE THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.